Jakafi Isn't the Whole Story: Why Incyte's Next Chapter Is Hematology and M&A
Incyte has been defined by Jakafi for years, but recent strategic moves - notably the $1.25 billion Vega acquisition for VGA039 and a healthy cash/FCF profile - suggest upside beyond its core JAK franchise. With a market cap near $25.3B, a PE around 15.7, and $1.92B of free cash flow, the risk-reward for a long swing-to-position trade looks favorab…